Edesa Biotech, Inc. 1,562,500 Common Shares (no par value per share) Amended and Restated Underwriting AgreementUnderwriting Agreement • February 26th, 2021 • Edesa Biotech, Inc. • Pharmaceutical preparations • New York
Edesa Biotech, Inc., a company incorporated under the laws of British Columbia, Canada (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 1,562,500 of its common shares (the “Firm Shares”), no par value per share (the “Common Shares”). In addition, the Company has granted to the Underwriters an option to purchase up to an additional 234,375 Common Shares as provided in Section 2. The additional 234,375 Common Shares that may be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares, are collectively called the “Offered Shares.” H.C. Wainwright & Co., LLC (“Wainwright”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters l
UNDERWRITER COMMON SHARE PURCHASE WARRANT EDESA BIOTECH, Inc.Security Agreement • February 26th, 2021 • Edesa Biotech, Inc. • Pharmaceutical preparations • New York
THIS UNDERWRITER COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) February 25, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Edesa Biotech, Inc., a corporation incorporated under the laws of British Columbia, Canada (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Shares, as defined in Section 1 herein. The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to the Underwriting Agreement, as defined in Section 1 herein.
